188 134

Cited 14 times in

Inactivation of bone morphogenetic protein 2 may predict clinical outcome and poor overall survival for renal cell carcinoma through epigenetic pathways.

DC FieldValueLanguage
dc.contributor.author장인익-
dc.date.accessioned2016-02-04T11:15:32Z-
dc.date.available2016-02-04T11:15:32Z-
dc.date.issued2015-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/140022-
dc.description.abstractWe investigated whether impaired regulation of bone morphogenetic protein-2 (BMP-2) via epigenetic pathways is associated with renal cell carcinoma (RCC) pathogenesis. Expression and CpG methylation of the BMP-2 gene were analyzed using RCC cell lines, and 96 matched RCC and normal renal tissues. We also performed functional analysis using BMP-2 restored RCC cells. A significant association of BMP-2 mRNA expression was also found with advanced tumor stage and lymph node involvement, while lower BMP-2 mRNA expression was significantly associated with poor overall survival after radical nephrectomy. In RCC cells, BMP-2 restoration significantly inhibited cell proliferation, migration, invasion, and colony formation. In addition, BMP-2 overexpression induced p21(WAF1/CIP1) and p27(KIP1) expression, and cellular apoptosis in RCC cells. BMP-2 mRNA expression was significantly enhanced in RCC cells by 5-aza-2'-deoxycitidine treatment. The prevalence of BMP-2 promoter methylation was significantly greater and BMP-2 mRNA expression was significantly lower in RCC samples as compared to normal kidney samples. Furthermore, a significant correlation was found between BMP-2 promoter methylation and mRNA transcription in tumors. Aberrant BMP-2 methylation and the resultant loss of BMP-2 expression may be a useful molecular marker for designing improved diagnostic and therapeutic strategies for RCC.-
dc.description.statementOfResponsibilityopen-
dc.format.extent9577~9591-
dc.relation.isPartOfONCOTARGET-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAged-
dc.subject.MESHAntimetabolites, Antineoplastic/pharmacology-
dc.subject.MESHApoptosis-
dc.subject.MESHAzacitidine/analogs & derivatives-
dc.subject.MESHAzacitidine/pharmacology-
dc.subject.MESHBone Morphogenetic Protein 2/biosynthesis-
dc.subject.MESHBone Morphogenetic Protein 2/genetics*-
dc.subject.MESHCarcinoma, Renal Cell/genetics*-
dc.subject.MESHCarcinoma, Renal Cell/metabolism-
dc.subject.MESHCarcinoma, Renal Cell/mortality-
dc.subject.MESHCarcinoma, Renal Cell/surgery-
dc.subject.MESHCell Line, Tumor-
dc.subject.MESHDNA Methylation*/drug effects-
dc.subject.MESHDown-Regulation-
dc.subject.MESHFemale-
dc.subject.MESHGene Expression Regulation, Neoplastic*/drug effects-
dc.subject.MESHGenes, cdc-
dc.subject.MESHHumans-
dc.subject.MESHKidney Neoplasms/genetics*-
dc.subject.MESHKidney Neoplasms/metabolism-
dc.subject.MESHKidney Neoplasms/mortality-
dc.subject.MESHKidney Neoplasms/surgery-
dc.subject.MESHKidney Tubules/metabolism-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeoplasm Proteins/biosynthesis-
dc.subject.MESHNeoplasm Proteins/genetics*-
dc.subject.MESHNephrectomy-
dc.subject.MESHPromoter Regions, Genetic/drug effects-
dc.subject.MESHPromoter Regions, Genetic/genetics-
dc.subject.MESHRNA, Messenger/biosynthesis-
dc.subject.MESHRNA, Messenger/genetics-
dc.subject.MESHRNA, Neoplasm/biosynthesis-
dc.subject.MESHRNA, Neoplasm/genetics-
dc.subject.MESHRecombinant Fusion Proteins/biosynthesis-
dc.subject.MESHRecombinant Fusion Proteins/genetics-
dc.subject.MESHTransfection-
dc.subject.MESHTreatment Outcome-
dc.titleInactivation of bone morphogenetic protein 2 may predict clinical outcome and poor overall survival for renal cell carcinoma through epigenetic pathways.-
dc.typeArticle-
dc.contributor.collegeCollege of Dentistry (치과대학)-
dc.contributor.departmentDept. of Oral Biology (구강생물학)-
dc.contributor.googleauthorYozo Mitsui-
dc.contributor.googleauthorHiroshi Hirata-
dc.contributor.googleauthorNaoko Arichi-
dc.contributor.googleauthorMiho Hiraki-
dc.contributor.googleauthorHiroaki Yasumoto-
dc.contributor.googleauthorInik Chang-
dc.contributor.googleauthorShinichiro Fukuhara-
dc.contributor.googleauthorSoichiro Yamamura-
dc.contributor.googleauthorVarahram Shahryari-
dc.contributor.googleauthorGuoren Deng-
dc.contributor.googleauthorSharanjot Saini-
dc.contributor.googleauthorShahana Majid-
dc.contributor.googleauthorRajvir Dahiya-
dc.contributor.googleauthorYuichiro Tanaka-
dc.contributor.googleauthorHiroaki Shiina-
dc.identifier.doi10.18632/oncotarget.3445-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA03461-
dc.relation.journalcodeJ02421-
dc.identifier.eissn1949-2553-
dc.identifier.pmid25797254-
dc.subject.keywordDNA methylation-
dc.subject.keywordbone morphogenetic protein 2-
dc.subject.keywordmolecular marker-
dc.subject.keywordrenal cell carcinoma-
dc.contributor.alternativeNameChang, In Ik-
dc.contributor.affiliatedAuthorChang, In Ik-
dc.rights.accessRightsfree-
dc.citation.volume6-
dc.citation.number11-
dc.citation.startPage9577-
dc.citation.endPage9591-
dc.identifier.bibliographicCitationONCOTARGET , Vol.6(11) : 9577-9591, 2015-
Appears in Collections:
2. College of Dentistry (치과대학) > Dept. of Oral Biology (구강생물학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.